Blood vessel hyperpermeability and pathophysiology in human tumour xenograft models of breast cancer: A comparison of ectopic and orthotopic tumours

BMC Cancer

Volumn 12, Issue , 2012, Pages

  Ho, Karyn S ^a,b   Poon, Peter C ^a   Owen, Shawn C ^a,b   Shoichet, Molly S ^a,b,c  

^a Department of Chemical Engineering and Applied Chemistry ^*  (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

Blood vessel hyperpermeability; Breast cancer; Ectopic transplantation; Enhanced permeability and retention; Nanomedicine; Orthotopic transplantation; Targeting; Tumour xenograft models

Indexed keywords

COLLAGEN TYPE 4; DEXTRAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BASEMENT MEMBRANE; BIOACCUMULATION; BLOOD VESSEL PERMEABILITY; BODY FLUID; BREAST CANCER; CANCER SIZE; CELL STRAIN; CELL STRAIN MDA MB 231 H2N; CONTROLLED STUDY; DENSITY; ECTOPIC TUMOR; ENDOTHELIUM CELL; IMMUNOHISTOCHEMISTRY; LIVER; LYMPH VESSEL; LYMPHATIC DRAINAGE; MOUSE; MOUSE STRAIN; NEOPLASM; NOD SCID GAMMA MOUSE; NONHUMAN; ORTHOTOPIC TUMOR; PATHOPHYSIOLOGY; PERICYTE; SKIN ULCER; SUBCUTANEOUS TISSUE TUMOR; TUMOR VASCULARIZATION; TUMOR XENOGRAFT;

ANIMALS; BREAST NEOPLASMS; CAPILLARY PERMEABILITY; FEMALE; HUMANS; LYMPHATIC VESSELS; MICE; MICE, INBRED NOD; MICE, SCID; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84870361165     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-12-579     Document Type: Article

References (37)

1. Teicher BA. Human tumor xenografts and mouse models of human tumors: re-discovering the models. Expert Opin Drug Dis 2009, 4(12):1295-1305.
2. Torchilin V. Tumor delivery of macromolecular drugs based on the EPR effect. Adv Drug Deliver Rev 2011, 63(3):131-135.
3. Fang J, Nakamura H, Maeda H. The EPR effect: unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv Drug Deliver Rev 2011, 63(3):136-151.
4. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000, 407(6801):249-257. 10.1038/35025220, 11001068.
5. Kerbel RS. Tumor angiogenesis: past, present and the near future. Carcinogenesis 2000, 21(3):505-515. 10.1093/carcin/21.3.505, 10688871.
6. Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer-chemotherapy - mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res 1986, 46(12):6387-6392.
7. Morikawa S, Baluk P, Kaidoh T, Haskell A, Jain RK, McDonald DM. Abnormalities in pericytes on blood vessels and endothelial sprouts in tumors. Am J Pathol 2002, 160(3):985-1000. 10.1016/S0002-9440(10)64920-6, 1867175, 11891196.
8. Dreher MR, Liu WG, Michelich CR, Dewhirst MW, Yuan F, Chilkoti A. Tumor vascular permeability, accumulation, and penetration of macromolecular drug carriers. J Natl Cancer I 2006, 98(5):335-344.
9. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005, 307(5706):58-62. 10.1126/science.1104819, 15637262.
10. Hashizume H, Baluk P, Morikawa S, McLean JW, Thurston G, Roberge S, Jain RK, McDonald DM. Openings between defective endothelial cells explain tumor vessel leakiness. Am J Pathol 2000, 156(4):1363-1380. 10.1016/S0002-9440(10)65006-7, 1876882, 10751361.
11. Sorensen AG, Batchelor TT, Zhang WT, Chen PJ, Yeo P, Wang MY, Jennings D, Wen PY, Lahdenranta J, Ancukiewicz M, et al. A "Vascular Normalization Index" as potential mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patients. Cancer Res 2009, 69(13):5296-5300. 10.1158/0008-5472.CAN-09-0814, 2824172, 19549889.
12. Hida K, Hida Y, Shindoh M. Understanding tumor endothelial cell abnormalities to develop ideal anti-angiogenic therapies. Cancer Sci 2008, 99(3):459-466. 10.1111/j.1349-7006.2007.00704.x, 18167133.
13. McDonald DM, Baluk P. Significance of blood vessel leakiness in cancer. Cancer Res 2002, 62(18):5381-5385.
14. Baluk P, Morikawa S, Haskell A, Mancuso M, McDonald DM. Abnormalities of basement membrane on blood vessels and endothelial sprouts in tumors. Am J Pathol 2003, 163(5):1801-1815. 10.1016/S0002-9440(10)63540-7, 1892429, 14578181.
15. Lu P, Weaver VM, Werb Z. The extracellular matrix: a dynamic niche in cancer progression. J Cell Biol 2012, 196(4):395-406. 10.1083/jcb.201102147, 3283993, 22351925.
16. Wu J, Akaike T, Maeda H. Modulation of enhanced vascular permeability in tumors by a bradykinin antagonist, a cyclooxygenase inhibitor, and a nitric oxide scavenger. Cancer Res 1998, 58(1):159-165.
17. Kerbel RS, Cornil I, Theodorescu D. Importance of orthotopic transplantation procedures in assessing the effects of transfected genes on human tumor-growth and metastasis. Cancer Metast Rev 1991, 10(3):201-215.
18. Killion JJ, Radinsky R, Fidler IJ. Orthotopic models are necessary to predict therapy of transplantable tumors in mice. Cancer Metast Rev 1998, 17(3):279-284.
19. Lunt SJ, Kalliomaki TMK, Brown A, Yang VX, Milosevic M, Hill RP. Interstitial fluid pressure, vascularity and metastasis in ectopic, orthotopic and spontaneous tumours. BMC Cancer 2008, 8:2. 10.1186/1471-2407-8-2, 2245966, 18179711.
20. Wilmanns C, Fan D, Obrian CA, Bucana CD, Fidler IJ. Orthotopic and ectopic organ environments differentially influence the sensitivity of murine colon-carcinoma cells to doxorubicin and 5-fluorouracil. Int J Cancer 1992, 52(1):98-104. 10.1002/ijc.2910520118, 1500231.
21. Francia G, Cruz-Munoz W, Man S, Xu P, Kerbel RS. Mouse models of advanced spontaneous metastasis for experimental therapeutics. Nat Rev Cancer 2011, 11(2):135-141. 10.1038/nrc3001, 21258397.
22. Holliday DL, Speirs V. Choosing the right cell line for breast cancer research. Breast Cancer Res 2011, 13(4):215. 10.1186/bcr2889, 3236329, 21884641.
23. Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol 2010, 17(6):1471-1474. 10.1245/s10434-010-0985-4, 20180029.
24. Tomayko MM, Reynolds CP. Determination of subcutaneous tumor size in athymic (Nude) mice. Cancer Chemoth Pharm 1989, 24(3):148-154.
25. Schiffelers RM, Metselaar JM, Fens MHAM, Janssen APCA, Molema G, Storm G. Liposome-encapsulated prednisolone phosphate inhibits growth of established tumors in mice. Neoplasia 2005, 7(2):118-127. 10.1593/neo.04340, 1501128, 15802017.
26. Ito M, Hiramatsu H, Kobayashi K, Suzue K, Kawahata M, Hioki K, Ueyama Y, Koyanagi Y, Sugamura K, Tsuji K, et al. NOD/SCID/gamma(null)(c) mouse: an excellent recipient mouse model for engraftment of human cells. Blood 2002, 100(9):3175-3182. 10.1182/blood-2001-12-0207, 12384415.
27. Cogger VC, McNerney GP, Nyunt T, DeLeve LD, McCourt P, Smedsrod B, Le Couteur DG, Huser TR. Three-dimensional structured illumination microscopy of liver sinusoidal endothelial cell fenestrations. J Struct Biol 2010, 171(3):382-388. 10.1016/j.jsb.2010.06.001, 3043550, 20570732.
28. Davies B, Morris T. Physiological parameters in laboratory-animals and humans. Pharmaceut Res 1993, 10(7):1093-1095.
29. Hori K, Saito S, Takahashi H, Sato H, Maeda H, Sato Y. Tumor-selective blood flow decrease induced by an angiotensin converting enzyme inhibitor, temocapril hydrochloride. Jpn J Cancer Res 2000, 91(2):261-269. 10.1111/j.1349-7006.2000.tb00940.x, 10761715.
30. Chen B, Pogue BW, Zhou XD, O'Hara JA, Solban N, Demidenko E, Hoopes PJ, Hasan T. Effect of tumor host microenvironment on photodynamic therapy in a rat prostate tumor model. Clin Cancer Res 2005, 11(2):720-727.
31. Tong RT, Boucher Y, Kozin SV, Winkler F, Hicklin DJ, Jain RK. Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res 2004, 64(11):3731-3736. 10.1158/0008-5472.CAN-04-0074, 15172975.
32. Kong G, Braun RD, Dewhirst MW. Hyperthermia enables tumor-specific nanoparticle delivery: effect of particle size. Cancer Res 2000, 60(16):4440-4445.
33. Abdelkarim M, Vintonenko N, Starzec A, Robles A, Aubert J, Martin M-L, Mourah S, Podgorniak M-P, Rodrigues-Ferreira S, Nahmias C, et al. Invading basement membrane matrix is sufficient for MDA-MB-231 breast cancer cells to develop a stable in vivo metastatic phenotype. PLoS One 2011, 6(8):e23334. 10.1371/journal.pone.0023334, 3156115, 21858074.
34. Perles-Barbacaru AT, van der Sanden BPJ, Farion R, Lahrech H. How stereological analysis of vascular morphology can quantify the blood volume fraction as a marker for tumor vasculature: comparison with magnetic resonance imaging. J Cerebr Blood F Met 2012, 32(3):489-501.
35. Rockson SG. Diagnosis and management of lymphatic vascular disease. J Am Coll Cardiol 2008, 52(10):799-806. 10.1016/j.jacc.2008.06.005, 18755341.
36. Schneider M, Ny A, Ruiz De Almodovar C, Carmeliet P. A new mouse model to study acquired lymphedema. PLoS Med 2006, 3(7):e264. 10.1371/journal.pmed.0030264, 1513046, 16842020.
37. Szuba A, Rockson SG. Lymphedema: anatomy, physiology and pathogenesis. Vasc Med 1997, 2(4):321-326.